Revolutionary Non-Surgical Hair Growth Treatment by Dr. Stuti Khare Shukla
Dr Stuti Khare Shukla, MD Dermatologist, fondly called as Hair Growth Queen of India & Celebrity Hair Specialist of Bollywood
Hair loss is now a problem which is alarmingly growing even in young population worldwide, and hair transplant surgeries are invasive as well as painful, Dr Stuti has unlocked the hair growth treatment with an innovative non surgical hair booster treatment without any downtime or need of hair transplant surgery
Innovating Non-Surgical Hair Restoration
Recognizing the emotional and psychological impact of hair loss, Dr. Shukla dedicated herself to finding effective, non-invasive solutions. Her relentless research culminated in the development of the Hair Growth Booster®, that offers a painless alternative to traditional hair transplant surgeries. This five-minute procedure has transformed the lives of over 80,000 patients, earning her the title 'Hair Growth Queen of India'.
Academic Excellence and Global Training
Pursuing her dreams with unwavering commitment, Dr. Shukla completed her MD in Dermatology. Her quest for knowledge led her to advanced training and fellowships across the globe, including prestigious institutions in the USA, Singapore, Paris, and Bangkok. This extensive education equipped her with a diverse skill set and a global perspective on non surgical hair growth treatment.
Fondly known as the Hair Growth Queen of India, Dr. Stuti has brought about a paradigm shift in hair restoration with her exclusive unmatched non-surgical Hair Growth Booster® treatment. This innovative approach is not just a treatment but a breakthrough solution for hair loss patients who seek painless and effective alternatives to traditional methods.
The Hair Growth Booster® is a quick, simple, five-minute procedure that has been hailed as a lifesaver for those suffering from hair loss. Unlike hair transplant surgeries, which are invasive, painful, show stopper and have a downtime.
The beauty of Dr. Stuti's signature treatment is its non invasive, zero downtime and patients experience noticeable improvements in hair density. Various researches have proved it to be more efficacious than conventional treatments such as PRP or minoxidil. This treatment's convenience and efficacy has made it a preferred choice for individuals around the globe, including those in U.S., Canada, Europe, who consult her through online consultation and the treatment products are delivered globally at doorstep, in the process clients are blissfully availing the treatment from the comfort of their homes.
Accolades and Recognitions
Dr. Shukla's innovative contributions have been widely recognized. She is TedX Speaker and was honored as the Youngest Dermatologist of India at the Indian Leadership Conclave in 2017. In 2020, she received the Power Woman of India award by Times, followed by the ET Inspiring Woman of India award in 2021. Her recent accolades include the ICEDATHON Innovator Award and the BW Healthcare 40 Under 40 distinction in 2023, and the Women Super Achiever Award by the Government of India and the Nav Bharat Times Healthcare Award in 2024.
Jury and Hair Care Expert of Femina Miss India 2024
In a testament to her expertise, Dr. Shukla collaborated with Femina Miss India 2024 as the official Hair Care Expert and served as a jury member. She is also the face behind Bollywood celebrities luscious hair who avail personalized hair consultations for maintaining healthy hair and enhancing their overall appearance.
Empowering Patients Globally
Dr. Shukla's impact extends beyond India. Through online consultations, she has reached patients worldwide, including those in the U.S., Canada, Europe, Australia, and the Middle East. Her personalized treatment plans have empowered individuals to regain their confidence without undergoing invasive procedures.
From the archives, client's testimonials for your immediate glance.
An overseas patient Vincenzo from Italy has achieved remarkable results with Dr SKS Hair Growth Booster! Without undergoing hair transplantation without the need to travel as it's an online treatment done, Mr Vincenzo saw amazing improvement and transformation in his male pattern baldness issue which helped him optimistically both in professional as well as on personal front.
Miss Anuja, a corporate professional from Hyderabad, approached Dr Stuti with Female Pattern Hair Loss. She was looking for a non invasive and trusted treatment as earlier she had undergone many treatments from many other doctors as well as homeopathy ayurveda treatment which dint work well for her. Over five months of consistent treatment with Dr Stuti, she experienced remarkable improvement
To share another incredible successful story, Mr Nawab from Dubai, who overcame Grade 5 Male Pattern Baldness with Dr Stuti's expert care!
After unsuccessful attempts with hair transplant surgery, multiple sessions of PRP, and GFC, Mr Nawab discovered Dr. Stuti's customized treatment approach. The customised non surgical Dr SKS Hair Booster treatment plan delivered exceptional results, with significant improvements in hair volume, density, and coverage.
Another patient, Mr. Vivek, from Bangalore, was battling severe hair loss due to Grade 5 Male Pattern Baldness. His condition not only impacted his appearance but also affected his confidence as he was required to get set for an important life milestone—marriage. The positive results boosted his confidence, helping him excel both professionally and personally.
Dr. Stuti Khare Shukla the renowned dermatologist and researcher, has several collaborations with with top labs in Paris and leading scientists worldwide. With over 10 publications in prestigious American journals, she's a key opinion leader and represents India at global conferences. Hair Growth Booster® has featured in Indian Medical Council-approved journals, earning international acclaim. Doctors globally get trained under her expertise, and her Instagram @dr.stutikhareshukla showcases remarkable patient results.
Dr. Stuti Khare Shukla in addition provides extended personalized consultation for Overseas and outstation patients via video call consultation on a regular basis
To book a consultation, call or WhatsApp +916261967835
Instagram page: https://instagram.com/dr.stutikhareshukla?igshid=ZDdkNTZiNTM=
Website: https://www.drstutikhareshukla.in/
Youtube: https://youtube.com/@DrStutiKhareShukla
Email Address: drstutikhareshukla@gmail.com
Disclaimer: Disclaimer: Content Produced by Elements of Aesthetics Clinics
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
16 hours ago
- Business Standard
G.C Chemie Pharmie: Four Decades of Innovation and Trust in Pharmaceuticals and Nutraceuticals
India PR Distribution Mumbai (Maharashtra) [India], June 6: G.C Chemie Pharmie Pvt. Ltd. (GCCPL), a pioneer in India's pharmaceutical, nutraceutical, functional foods, and biopharmaceutical sectors, proudly celebrates over 44 years of innovation and service excellence. Founded in 1981 by visionary entrepreneur Gautam Shah, GCCPL has evolved into a globally connected and innovation-driven enterprise known for its commitment to trust, transparency, and quality. What began as an API trading and distribution firm has transformed into a diversified pharmaceutical powerhouse. GCCPL's impressive timeline of achievements includes: - 2009/2010: Acquisition of Eagle Chemical Works, establishing its own API manufacturing capabilities - 2009: Release of its first vaccine, marking a significant milestone in biopharmaceuticals - 2010/2011: Launch of its P2P division, introducing affordable medicines to the Indian market -2018: Entry into the sports nutrition space - 2022: Creation of a preventive healthcare division with a focus on gynecology and orthopedics - 2023: Establishment of a dedicated vaccine division to expand immunization solutions Driven by a mission to lead through innovative thinking and technology adoption, GCCPL delivers tailored solutions across pharmaceutical, nutraceutical, and functional food categories. The company continues to differentiate itself through its strong regulatory acumen, cutting-edge R & D, and a global network of manufacturing and distribution partners. "At GCCPL, innovation is not a buzzword--it's the foundation of our growth strategy," said Founder and Chairman Gautam Shah. "We're proud to be one of India's few private companies to bring the pneumococcal vaccine to the domestic market, second only to Pfizer." Recent product highlights include UC-II®, a patented undenatured type II collagen supplement, and Pylopass™, a breakthrough strain-based probiotic--both showcasing GCCPL's commitment to introducing clinically backed, innovative health solutions to India. With a sterling reputation for regulatory compliance, deep market research, and financial integrity--as affirmed by CRISIL's highest rating A2+ GCCPL stands as a trusted partner for businesses and healthcare providers seeking reliable, next-generation healthcare products. About G.C Chemie Pharmie Pvt. Ltd. Founded in 1981, GCCPL is an Indian-based pharmaceutical and nutraceutical company with a global footprint. Known for its reliability, innovation, and commitment to quality, GCCPL offers customized, technology-driven healthcare solutions to meet the evolving needs of today's market. The company maintains a strong presence in vaccines, preventive care, functional foods, and advanced supplements.
United News of India
a day ago
- United News of India
Dr Reddy's Lab partners with Alvotech to Co-Develop & commercialize Biosimilar Candidate
Hyderabad, June 5 (UNI) Alvotech , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Hyderabad-based Dr. Reddy's Laboratories Ltd, on Thursday announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancerTypes, Hyderabad based pharma giant said in a release here. In 2024, worldwide sales of Keytruda were US$29.5 billion. The collaboration combines and Alvotech's proven capabilities in biosimilars, thereby speeding up the development process and extending the global reach for this biosimilar candidate. Under the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally. 'We are very pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R& D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets. It further enables us to increase the availability of cost-effective, critical biologic medications to patient's world-wide,' said Róbert Wessman, chairman and CEO of Alvotech. Dr Reddy's CEO Erez Israeli said 'We are happy to collaborate with Alvotech for the pembrolizumab biosimilar. This demonstrates our ability to develop and manufacture high quality and affordable treatment options for patients worldwide. Additionally, oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of themost critical therapies in immuno-oncology.' UNI KNR BD
Business Standard
2 days ago
- Business Standard
Servier India introduces 'Ivosidenib'(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
VMPL Mumbai (Maharashtra) [India], June 5: Servier India, a subsidiary of the leading French pharmaceutical Servier Group, today announced the launch of Ivosidenib (Tibsovo®), an oral targeted therapy approved in the management of cancer patients with Acute Myeloid Leukemia (AML) and Cholangiocarcinoma, with an isocitrate dehydrogenase-1 (IDH1) mutation. Servier India received the approval on 14th May 2025, from Central Drugs Standard Control Organisation (CDSCO) for the import, sale, and distribution of the medication. Acute myeloid leukemia is a challenging hematological malignancy. Studies indicate that only about 30-40% of AML patients in India receive adequate treatment1, with high mortality rates due to rapid disease progression and infections. Cholangiocarcinomas (CCA) are rare tumours originating from bile duct. Due to their asymptomatic nature they are usually diagnosed when the disease is advanced.2 The announcement marks a significant advancement in management of the mentioned rare and difficult-to-treat cancers in India, addressing a critical unmet medical need. Speaking on the occasion, Mr. Aurelien Breton, Managing Director, Servier India, said, "Our focus is to advance oncology care by bringing innovative, precision medicines to patients who need them the most. By prioritizing access and working to make treatment options affordable to patients, we are dedicated to bridging critical gaps in cancer care across the country. This launch is a significant step forward in our mission to support healthcare providers with targeted treatment options and ultimately improve survival outcomes and quality of life for patients throughout India." IDH1 mutation occurs in approximately 7-14% of AML patients in India3, making targeted mechanisms especially relevant for this subset. "This therapy represents a significant therapeutic option in the treatment of AML and Cholangiocarcinoma. For healthcare professionals, this precision therapy offers a new, effective option that can improve patient outcomes where traditional treatments have limited success. It highlights the benefits of targeted therapy and caliber of innovation in enhancing lives and advancing cancer care in India.", highlighted Dr. Pranav Sopory, Medical and Patient Affairs Director, Servier India. Speaking on the importance of treatment access, Ms. Pratima Tripathi, Commercial Director, Servier India, said: "Our foremost priority is to ensure that the therapy is accessible and affordable to patients across India. We are actively collaborating with healthcare providers, patient advocacy groups, and policymakers to remove barriers and facilitate timely access to this important therapy. Through these partnerships, we are committed to expanding treatment options and making a meaningful difference in the lives of patients." By introducing these advanced therapies, Servier India reaffirms its commitment to advancing innovative cancer treatments that improve clinical outcomes and enhance the quality of life of patients. Disclaimer: This press release is intended solely to share regulatory and medical information regarding the launch; the reference to "Tibsovo" is not intended as a promotional or public advertisement. Use of the therapy is strictly based on a doctor's prescription and clinical discretion. About Servier India Servier India has been committed for over three decades to delivering innovative pharmaceutical solutions that improve the lives of patients and their families across India. Established in 1985 as an affiliate of the leading independent French pharmaceutical Servier Group, the company focuses on therapeutic areas such as Cardiometabolism, Neuroscience, Venous Diseases, and Oncology. Servier India has a strong pan-India presence and a dedicated workforce of around 580 that strives to address critical healthcare challenges with passion and purpose. As part of Servier group operating in over 150 countries, Servier India inherits a rich legacy of scientific excellence and patient-centric innovation. Globally, Servier invests heavily in research and development, focusing on our key therapeutic areas. About Servier Servier is a global pharmaceutical group governed by a Foundation that aspires to serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. As a world leader in cardiometabolism and venous diseases, Servier's ambition is to become a focused and innovative player in oncology by targeting rare cancers. Headquartered in France, Servier relies on a strong geographical footprint; its medicines are available in close to 140 group achieved a revenue of EUR5.9 billion in 2024. Additional Details on Ivosidenib Internationally, Ivosidenib has already received regulatory approvals in more than 42 countries, including the USA, Europe, China, UAE, and South Korea. In the United States, the US FDA approved it in 2019 as a monotherapy and later in May 2022 as a combination treatment with Azacitidine for patients aged 75 and above, or those who cannot tolerate intensive chemotherapy. The European Medical Agency (EMA) gave its approval in May 2023 for use in patients who are not fit for standard induction chemotherapy. In India, the process moved forward in April 2025, when the Subject Expert Committee (SEC) gave a positive recommendation for Ivosidenib. Following this, the DCGI granted approval for the marketing authorization in May 2025
